2.92
price down icon1.35%   -0.04
pre-market  Pre-market:  2.87   -0.05   -1.71%
loading
Bioline Rx Ltd Adr stock is traded at $2.92, with a volume of 68,725. It is down -1.35% in the last 24 hours and down -12.84% over the past month. BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
See More
Previous Close:
$2.96
Open:
$3.06
24h Volume:
68,725
Relative Volume:
0.01
Market Cap:
$10.39M
Revenue:
-
Net Income/Loss:
$-60.61M
P/E Ratio:
-3.2444
EPS:
-0.9
Net Cash Flow:
$-22.91M
1W Performance:
-12.57%
1M Performance:
-12.84%
6M Performance:
+440.74%
1Y Performance:
+239.46%
1-Day Range:
Value
$2.85
$3.1295
1-Week Range:
Value
$2.85
$3.34
52-Week Range:
Value
$0.0815
$4.44

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
Name
Bioline Rx Ltd Adr
Name
Phone
-
Name
Address
-
Name
Employee
79
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
BLRX's Discussions on Twitter

Compare BLRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BLRX
Bioline Rx Ltd Adr
2.92 10.39M 0 -60.61M -22.91M -0.90
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-18-17 Upgrade Maxim Group Hold → Buy
Feb-13-17 Initiated Rodman & Renshaw Buy
Aug-12-16 Downgrade Maxim Group Buy → Hold
Aug-17-15 Reiterated Maxim Group Buy
Jul-27-15 Reiterated ROTH Capital Buy
Jun-22-15 Initiated JMP Securities Mkt Outperform
View All

Bioline Rx Ltd Adr Stock (BLRX) Latest News

pulisher
Apr 01, 2025

BioLineRx stock rating cut to Hold at Jones Trading - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks

Mar 31, 2025
pulisher
Mar 07, 2025

Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 27, 2025

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 19, 2025

BLRX: Aphexda Transition Progressing - Research Tree

Feb 19, 2025
pulisher
Jan 31, 2025

BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India

Jan 31, 2025
pulisher
Jan 21, 2025

BioLineRx announces strategic shift with licensing deals - Investing.com

Jan 21, 2025
pulisher
Jan 21, 2025

BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks

Jan 21, 2025
pulisher
Jan 17, 2025

BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks

Jan 17, 2025
pulisher
Jan 17, 2025

BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan

Jan 17, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 07, 2025

BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks

Jan 07, 2025
pulisher
Jan 06, 2025

BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks

Jan 06, 2025
pulisher
Dec 16, 2024

BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 06, 2024

BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India

Dec 06, 2024
pulisher
Nov 26, 2024

BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com

Nov 26, 2024
pulisher
Nov 25, 2024

BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx earnings beat by $0.04, revenue topped estimates - Investing.com India

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa

Nov 25, 2024
pulisher
Nov 25, 2024

BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks

Nov 25, 2024
pulisher
Nov 25, 2024

IO Biotech Inc (NASDAQ: IOBT) Is A Buzzing Hot Stock - Stocks Register

Nov 25, 2024
pulisher
Nov 25, 2024

Options Volatility and Implied Earnings Moves Today, November 25, 2024 - TipRanks

Nov 25, 2024
pulisher
Nov 22, 2024

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance

Nov 22, 2024
pulisher
Nov 21, 2024

BioLineRx stock hits 52-week low at $0.38 amid market challenges - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

SEC Form 424B5 filed by BioLineRx Ltd. - Quantisnow

Nov 21, 2024
pulisher
Nov 20, 2024

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 - Benzinga

Nov 20, 2024
pulisher
Nov 20, 2024

BioLineRx to Report Q3 2024 Financial Results on November 25 - StockTitan

Nov 20, 2024
pulisher
Nov 12, 2024

BioLineRx Granted Extension to Meet Nasdaq Requirements - TipRanks

Nov 12, 2024
pulisher
Nov 05, 2024

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

Nov 05, 2024
pulisher
Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024
pulisher
Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024
pulisher
Oct 07, 2024

Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex

Oct 07, 2024
pulisher
Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024

Bioline Rx Ltd Adr Stock (BLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Cap:     |  Volume (24h):